François-Xavier Gros

Père, Epoux, Hématologue @ChuBordeaux (Lymphomes, CAR-T cells), Plongeur, E-sport!

[SwissBorg @swissborg]

Most parents know they should invest for their child's future. So why do so few actually do it? 👀

It's rarely the money. It's remembering, deciding and staying consistent for eighteen years.

Auto-Invest takes care of the habit. The Kids Bundle takes care of the portfolio.

Every contribution is split across three pillars, Stability, Growth and Protection.

No exchange fees, even on scheduled buys.

Two automatic systems. Just one decision from you. 💚

https://t.co/9OkjFlWxNo

Engineered in Switzerland 🇨🇭
Licensed in Europe 🇪🇺
Growing Wealth Together.

[SwissBorg @swissborg]

Why should your onchain wealth have to live in dollars?

Around 99% of stablecoin value still does. But we believe wealth should be manageable in your own currency.

Today SwissBorg joins the Eurøpe Consortium, the first European cross-company coalition built around a regulated euro stablecoin.

$EUROP is already supported in the SwissBorg app. Deposit, withdraw, and exchange it with 400+ crypto assets, and opt in to Smart Cash for monthly BORG loyalty rewards.

Now we help build the wider market for euros onchain.

Read the full announcement: https://t.co/zzUVWlSdfh

Engineered in Switzerland 🇨🇭
Licensed in Europe ��🇺
Growing Wealth Together.

[SwissBorg @swissborg]

Wondering where solana:3dQTr7ror2QPKQ3GbBCokJUmjErGg8kTJzdnYjNfvi3Z is? 👀

The Top Trending Risers chart shows which tokens are climbing fastest, the biggest jumps in trending score over 24 hours. BORG is not a riser because it rarely ever leaves the top!

The current Top Five Trending tokens overall:

🥇 $BTC
🥈 solana:3dQTr7ror2QPKQ3GbBCokJUmjErGg8kTJzdnYjNfvi3Z
🥉 solana:So11111111111111111111111111111111111111112
4️⃣ ethereum:native
5️⃣ ripple:native

Consistently in the hive mind's sights. 💚

[TheSwissKraken @TheSwissKraken]

L'alpha qui se cache dans l'app, ce n'est pas toujours le prix. 👀

Dans l'onglet Trending, via @swissborg , tu vois où la communauté bouge vraiment :
trades, recherches, transactions classés grâce à l'activité réelle, pas sur le pump du jour.

C'est un thermomètre de l'attention des Borgers.
Perso, je jette un œil avant d'ouvrir un ordre, juste pour calibrer le bruit du marché.

#GuardiansAd ethereum:0x64d0f55cd8c7133a9d7102b13987235f486f2224

[François-Xavier Gros @FXGros]

@swissborg @litecoin @Zcash Soon in "Earn"?

[VJHemOnc @VJHemOnc]

We are thrilled to once again be the official media partner for the annual EBMT-EHA European CAR T-cell Meeting, which will take place in Palma de Mallorca, Spain, from 12–14 February! 🇪🇸

Want to join us there or attend virtually?

Register here:
👉 https://t.co/TAhBrN1dgd..

#ImmunoOnc #CARTCell #CART26 @TheEBMT @EHA_Hematology

[Uriel Suárez @UsuarezMD]

VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies - The Lancet https://t.co/7qgELWntz7

[François-Xavier Gros @FXGros]

@moonlaggoune Très partant! Abonné Finary plus :-)

[Graham Collins @graham74GC]

Intriguing data from Luan et al. Time of CAR-T infusion may influence outcome.
• multicentre retrospect, 1052 pts
• rel / ref DLBCL
• med infn time 11.48am
• every hr later assoc with worse outcome
• 1y PFS 51% < 12pm, 35% > 12pm
#lymsm

https://t.co/D6j718GRqB

[Mostafa Faisal @MostafaFaisal14]

Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma @BloodCancerJnl
https://t.co/TJ83Nsda7u

[François-Xavier Gros @FXGros]

@sjowall69 Merci pour ce thread. Il y a aussi une plus value sur la valeur de la maison à prendre en compte non?

[Mostafa Faisal @MostafaFaisal14]

Outcomes of CART in THRBCL

[Mostafa Faisal @MostafaFaisal14]

Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: A multicentre real-world study @BrJHaem
https://t.co/cIPD5I4S7b

[François-Xavier Gros @FXGros]

@topcao @DokPepper Après une chirurgie de base du crâne?

[Graham Collins @graham74GC]

Desai et al - PD1i based salvage assoc with better post ASCT outcomes in Hodgkin.
• 1261 pts, 25% had PD1i any time pre auto
• 2y PFS 88.2% v 70.2% if prior PD1i vs chemo &/or BV
PD1i salvage is preferred approach - still in era of 1L nivo-AVD?
#lymsm

https://t.co/LT1ZkuOywL

[TheNCSmaster @TheNCSmaster]

It’s that time of year

[Vincent Rajkumar @VincentRK]

Check out full set of myeloma algorithms in this thread.

[British Journal of Haematology @BrJHaem]

🔹 @BritSocHaem Guideline🔹
Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline
https://t.co/MYWkIr5rHd

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology

Real-world #RWE treatment patterns and clinical outcomes among patients with diffuse large B-cell #lymphoma #DLBCL in a US healthcare claims database

https://t.co/MKAj7X4Irq

#lymsm

[Toby Eyre @tobyeyre82]

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma https://t.co/GintYFlgAn